Delayed expectations for China’s patent reform
Patent law amendments may not be among the National People’s Congress’ priorities
Four months after China signed a “Phase One” trade deal with the U.S., patent law amendments may not be among the priorities of the National People’s Congress, leaving it unclear when expected pharmaceutical patent protections could materialize.
China has long discussed IP reforms, including a proposed amendment to its patent law that would protect innovative biopharmaceutical companies; however, concrete changes have not quickly followed.
In January 2019, the National People’s Congress (NPC) published a